Friday, September 29, 2006

New Copy-Cat Drug To Be Introduced By J&J

Johnson & Johnson will soon launch paliperidone, a once-a-day schizophrenia drug, the company hopes it will pass the FDA handily. The new drug is derived directly from Risperdal, a schizophrenia drug and J&J's best-selling product last year, with sales of $3.55 billion.
After a patient swallows a dose of Risperdal, usually a tablet a day, the liver transforms the medicine into paliperidone, the active substance inside the body. By marketing paliperidone as a new drug, J&J would perform this act of metabolism inside the lab; the new pill would release the chemical over 24 hours. J&J expects paliperidone, if approved, to bring five more years of marketing life to its antipsychotics line.

So by switching from the soon to be generic and inexpensive Risperdal to the new high priced paliperidone you can save your liver all that valuable energy of metabolization. Look for J&J to soon start vilifying their old drug Risperdal and touting their new wonder drug paliperidone. I am sure they will have a new study that shows left handed Albanians that are uncircumcised had statistically significant lower side effects with paliperidone than with Risperidal.

Other copycats have included Schering-Plough Corp.'s Clarinex, an antihistamine that replaced Claritin. Likewise, Forest Laboratories introduced the antidepressant Lexapro, a derivative of the antidepressant Celexa that has gone on to supplant Celexa as the company's best-seller. AstraZeneca PLC's purple Nexium pills replaced Prilosec. Nexium has become AstraZeneca's best-selling drug, as Prilosec once was, with $4.63 billion in sales last year.
DAM J.A.M. Bicycle Tour